S&P 500   4,967.23
DOW   37,986.40
QQQ   414.65
Biden signs bill extending a key US surveillance program after divisions nearly forced it to lapse
MarketBeat Week in Review – 4/15 - 4/19
The drug war devastated Black and other minority communities. Is marijuana legalization helping?
Morning sickness? Prenatal check-ups? What to know about new rights for pregnant workers
A man escaped Sudan's bloody civil war. His mysterious death in Missisippi has sparked suspicion
Record Store Day celebrates indie retail music sellers as they ride vinyl's popularity wave
Panama Papers trial's public portion comes to an unexpectedly speedy end
S&P 500   4,967.23
DOW   37,986.40
QQQ   414.65
Biden signs bill extending a key US surveillance program after divisions nearly forced it to lapse
MarketBeat Week in Review – 4/15 - 4/19
The drug war devastated Black and other minority communities. Is marijuana legalization helping?
Morning sickness? Prenatal check-ups? What to know about new rights for pregnant workers
A man escaped Sudan's bloody civil war. His mysterious death in Missisippi has sparked suspicion
Record Store Day celebrates indie retail music sellers as they ride vinyl's popularity wave
Panama Papers trial's public portion comes to an unexpectedly speedy end
S&P 500   4,967.23
DOW   37,986.40
QQQ   414.65
Biden signs bill extending a key US surveillance program after divisions nearly forced it to lapse
MarketBeat Week in Review – 4/15 - 4/19
The drug war devastated Black and other minority communities. Is marijuana legalization helping?
Morning sickness? Prenatal check-ups? What to know about new rights for pregnant workers
A man escaped Sudan's bloody civil war. His mysterious death in Missisippi has sparked suspicion
Record Store Day celebrates indie retail music sellers as they ride vinyl's popularity wave
Panama Papers trial's public portion comes to an unexpectedly speedy end
S&P 500   4,967.23
DOW   37,986.40
QQQ   414.65
Biden signs bill extending a key US surveillance program after divisions nearly forced it to lapse
MarketBeat Week in Review – 4/15 - 4/19
The drug war devastated Black and other minority communities. Is marijuana legalization helping?
Morning sickness? Prenatal check-ups? What to know about new rights for pregnant workers
A man escaped Sudan's bloody civil war. His mysterious death in Missisippi has sparked suspicion
Record Store Day celebrates indie retail music sellers as they ride vinyl's popularity wave
Panama Papers trial's public portion comes to an unexpectedly speedy end

Bausch Health Companies (BHC) Stock Forecast & Price Target

$8.69
+0.09 (+1.05%)
(As of 04/19/2024 ET)

Bausch Health Companies Consensus Analyst Rating and Stock Price Forecast (2024)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Analysts' Consensus Rating

Hold
Based on 3 Analyst Ratings

Analysts' Consensus Price Target

$13.00
49.60% Upside
High Forecast$14.00
Average Forecast$13.00
Low Forecast$12.00
TypeCurrent Forecast
4/21/23 to 4/20/24
1 Month Ago
3/22/23 to 3/21/24
3 Months Ago
1/21/23 to 1/21/24
1 Year Ago
4/21/22 to 4/21/23
Consensus Rating
Hold
Hold
Hold
Hold
Strong Buy
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
Buy
1 Buy rating(s)
1 Buy rating(s)
1 Buy rating(s)
0 Buy rating(s)
Hold
2 Hold rating(s)
2 Hold rating(s)
2 Hold rating(s)
4 Hold rating(s)
Sell
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
Consensus Price Target$13.00$11.50$12.50$10.60
Predicted Upside49.60% Upside29.72% Upside44.26% Upside42.23% Upside
Get Bausch Health Companies Upgrade and Downgrade Alerts

Sign-up to receive the latest news and ratings for BHC and its competitors with MarketBeat's FREE daily newsletter.

BHC Analyst Ratings By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.
Skip Chart & View Analyst Rating History

BHC Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.
Skip Chart and View Analyst Price Target HistorySkip Chart & View Price History Table

Bausch Health Companies Stock vs. The Competition

TypeBausch Health CompaniesMedical CompaniesS&P 500
Consensus Rating Score
2.33
2.68
2.49
Consensus RatingHoldModerate BuyHold
Predicted Upside49.60% Upside1,020.83% Upside11.93% Upside
News Sentiment RatingPositive News
Positive News
Positive News

Recent Analyst Ratings and Stock Forecasts

DateBrokerageAnalyst NameActionRatingPrice TargetUpside/Downside on Report DateDetails
4/12/2024Royal Bank of Canada
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Reiterated RatingSector Perform ➝ Sector Perform$12.00+39.53%
2/20/2024Jefferies Financial Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetBuy$16.00 ➝ $14.00+63.17%
6/16/2023TD Cowen
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 DowngradeOutperform ➝ Market Perform

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Saturday at 08:05 PM ET.

BHC Price Target - Frequently Asked Questions

What is Bausch Health Companies's consensus rating and price target?

According to the issued ratings of 3 analysts in the last year, the consensus rating for Bausch Health Companies stock is Hold based on the current 2 hold ratings and 1 buy rating for BHC. The average twelve-month price prediction for Bausch Health Companies is $13.00 with a high price target of $14.00 and a low price target of $12.00. Learn more on BHC's analyst rating history.

Do Wall Street analysts like Bausch Health Companies more than its competitors?

Analysts like Bausch Health Companies less than other Medical companies. The consensus rating for Bausch Health Companies is Hold while the average consensus rating for medical companies is Moderate Buy. Learn more on how BHC compares to other companies.

Does Bausch Health Companies's stock price have much upside?

According to analysts, Bausch Health Companies's stock has a predicted upside of 51.34% based on their 12-month stock forecasts.

What analysts cover Bausch Health Companies?

Bausch Health Companies has been rated by Jefferies Financial Group, and Royal Bank of Canada in the past 90 days.


Stock Ratings Reports and Tools

This page (NYSE:BHC) was last updated on 4/20/2024 by MarketBeat.com Staff

From Our Partners